Clinical Trials on Recurrent Myelodysplastic/Myeloproliferative Neoplasm in Portugal

Total 42 results

Portuguese Oncology Institute, Coimbra

Completed

Follow-up Protocol of Colorectal Endoscopic Mucosal Resection Scars

Colorectal Cancer | Recurrence, Local Neoplasm

Portugal
Novartis Pharmaceuticals

Recruiting

Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma

Newly Diagnosed and Recurrent Glioblastoma

Spain, Israel, Portugal
Catharina Ziekenhuis Eindhoven

Recruiting

Induction Chemotherapy for Locally Recurrent Rectal Cancer (PelvEx II)

Recurrent Rectal Cancer

Netherlands, Sweden, Belgium, Norway, Portugal
Centro Hospitalar de Lisboa Central
Ophiomics - Precision Medicine

Recruiting

HepatoPredict Prognostic Tool for the Decision of Liver Transplant in Hepatocellular Carcinoma (HepatoPredict)

Recurrence Tumor | Hepatocellular Carcinoma, Scirrhous

Portugal
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

China, Czechia, Japan, Saudi Arabia, Taiwan, Turkey, Germany, Spain, Netherlands, Italy, Singapore, Australia, Austria, France, United Kingdom, Korea, Republic of, Thailand, Israel, Belgium, Canada, Switzerland, Lithuania, Russian Federation and more
European Organisation for Research and Treatment...

Unknown

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Anemia

Belgium, Switzerland, Czech Republic, Portugal, Austria, Netherlands, Slovakia
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

France, Belgium, Portugal
Radboud University Medical Center

Recruiting

A Prospective, Multicentre European Registry for Newly Diagnosed Patients With Myelodysplastic Syndromes (EUMDS)

Myelodysplastic Syndromes (MDS)

Denmark, Switzerland, Serbia, Austria, Croatia, Czechia, France, Germany, Greece, Israel, Italy, Netherlands, Poland, Portugal, Romania, Spain, Sweden, United Kingdom
Kiadis Pharma

Completed

Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

Canada, Belgium, Germany, Croatia, United Kingdom, Portugal
Gamida Cell ltd

Active, not recruiting

Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Lymphoma | Acute Leukemia | Hematological Malignancies | Acute Lymphoblastic Leukemia (ALL) | Myelodysplastic Syndrome (MDS) | Acute Myelogenous Leukemia (AML) | Chronic Myelogenous Leukemia (CML)

Spain, United States, United Kingdom, Israel, Singapore, Brazil, Italy, France, Netherlands, Portugal
Celgene

Completed

A Study of Lenalidomide Versus Placebo in Subjects With Transfusion Dependent Anemia in Lower Risk Myelodysplastic Syndrome (MDS) Without Del 5q (MDS-005)

Anemia

United States, Belgium, Spain, United Kingdom, Austria, Canada, Germany, Portugal, France, Australia, Israel, Japan, Italy, Czechia, Poland, Turkey
Sanofi

Completed

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis (JAKARTA)

Hematopoietic Neoplasm

Austria, Germany, Italy, Spain, United Kingdom, France, Belgium, Israel, Sweden, Australia, United States, Lithuania, Portugal, Korea, Republic of, Singapore, Taiwan, Mexico, Brazil, Canada, Hungary, Ireland, Poland, Romania, Russian... and more
Takeda

Completed

A Study of People With Multiple Myeloma (MM) in Portugal (CharisMMa-Portugal)

Relapse and/or Refractory Multiple Myeloma

Portugal
Kiadis Pharma

Terminated

Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States, Canada, Netherlands, Israel, Germany, United Kingdom, Belgium, Italy, Sweden, Croatia, Spain, France, Portugal
BioNTech SE

Recruiting

A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT)

Recurrent Head and Neck Cancer | Unresectable Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Cancer

Germany, United States, France, United Kingdom, Korea, Republic of, Spain, Poland, Belgium, Brazil, Taiwan, Italy, Canada, Czechia, Australia, Turkey, Mexico, Chile, Argentina, Austria, Hungary, Portugal, Sweden
AstraZeneca
RTI Health Solutions; A+A Healthcare Marketing Research; Freelance CRA (FCRA)

Completed

OSCA - Olaparib Standard of CAre Study (OSCA)

Platinum-sensitive Recurrent Serous Ovarian Cancer

France, Italy, Korea, Republic of, Spain, United Kingdom, Germany, Belgium, Israel, Portugal, Netherlands, Switzerland, Canada, Australia
Gilead Sciences

Terminated

Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS) (ENHANCE)

Myelodysplastic Syndromes

United States, Spain, Belgium, Australia, France, Hong Kong, Hungary, Finland, New Zealand, Germany, Netherlands, United Kingdom, Italy, Switzerland, Portugal, Canada, Austria, Czechia, Norway, Poland, Turkey
Novartis Pharmaceuticals

Completed

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Polycythemia Vera

Germany, Belgium, France, Austria, Canada, Thailand, Norway, Bulgaria, Portugal, Chile, Mexico, Sweden
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Celgene

Completed

An Efficacy and Safety Study of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Adults With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly Patients With Acute Myeloid Leukemia (AML)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Canada, Spain, United Kingdom, United States, France, Austria, Germany, Italy, Netherlands, Belgium, Portugal, Poland
Celgene

Completed

The Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo and Best Supportive Care in Subjects With Red Blood Cell (RBC) Transfusion-Dependent Anemia and Thrombocytopenia Due to International Prognostic Scoring System (IPSS) Low Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States, Australia, Canada, Czechia, France, Germany, Italy, Korea, Republic of, Mexico, Poland, Sweden, United Kingdom, Belgium, Brazil, Denmark, Finland, Greece, Israel, Netherlands, Norway, Portugal, Spain, Turkey
European LeukemiaNet

Completed

European Stop Tyrosine Kinase Inhibitor Study (EURO-SKI)

Chronic Myeloid Leukemia

France, Denmark, Norway, Sweden, Czechia, Portugal, Germany, Netherlands, Finland, Greece
Protagonist Therapeutics, Inc.

Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

Polycythemia Vera

United States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
Bristol-Myers Squibb

Terminated

Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib

Leukemia, Myeloid, Chronic

Sweden, United Kingdom, Russian Federation, France, Germany, Belgium, Portugal, Finland, Norway, Spain, Italy
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Hematologic Diseases | Chronic Myelogenous Leukemia | CML | Leukemia, Myeloid Chronic

Taiwan, Italy, Spain, United Kingdom, Germany, United States, Korea, Republic of, France, Russian Federation, Canada, Denmark, Poland, Portugal, Austria, Czechia
Elypta

Recruiting

AURORAX-0087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC (AUR87A)

Clear Cell Renal Cell Carcinoma

United States, Sweden, United Kingdom, France, Denmark, Finland, Canada, Italy, Portugal, Spain
Novartis Pharmaceuticals

Recruiting

Asciminib Roll-over Study

Leukemia, Myelogenous, Chronic, BCR-ABL Positive | Chronic Myelogenous Leukemia

Denmark, Spain, France, Germany, Lebanon, Italy, Argentina, Czechia, Portugal, United Kingdom, Brazil, Mexico, Russian Federation, Taiwan, Austria, Canada, Korea, Republic of, Turkey, United States, Singapore, Japan, Bulgaria, Poland, Romani... and more
Ariad Pharmaceuticals

Terminated

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Chronic Myeloid Leukemia

United States, Australia, Austria, Belgium, Canada, Czech Republic, Finland, France, Germany, Hong Kong, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, Slovakia, Spain, Sweden, Switz... and more
Amgen

Completed

A Study Evaluating the Efficacy and Safety of ABP 959 Compared With Eculizumab in Adult Participants With PNH (DAHLIA)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Italy, United States, Norway, Czechia, United Kingdom, Slovenia, Netherlands, Turkey, Portugal, Finland, France, Ireland, Sweden
Bayer

Recruiting

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Biochemically Recurrent Prostate Cancer

Austria, Spain, United States, Australia, Brazil, France, Germany, Taiwan, Denmark, China, Netherlands, Portugal, Japan, Canada, Finland, Italy, Hungary, United Kingdom, Poland, Israel, New Zealand, Sweden, Belgium, Czechia
Hoffmann-La Roche

Terminated

A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy (SANDPIPER)

Breast Cancer

Italy, United States, Korea, Republic of, Canada, Czechia, Spain, Australia, Bulgaria, China, Finland, France, Greece, Poland, Portugal, Taiwan, Thailand, Turkey, Colombia, Bosnia and Herzegovina, Mexico, Peru, Romania, Russian Federation and more
Takeda

Active, not recruiting

Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses (OPTIC)

Myeloid Leukemia, Chronic, Chronic Phase

United States, Spain, Taiwan, Australia, Canada, Russian Federation, Sweden, Switzerland, Germany, United Kingdom, Poland, Korea, Republic of, Argentina, Hong Kong, Singapore, Italy, Chile, Czechia, Denmark, France, Portugal
Kartos Therapeutics, Inc.

Recruiting

KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment (BOREAS)

Primary Myelofibrosis (PMF) | Post-Polycythemia Vera MF (Post-PV-MF) | Post-Essential Thrombocythemia MF (Post-ET-MF)

United States, Korea, Republic of, Germany, Australia, Hungary, France, Spain, Italy, Taiwan, Thailand, Brazil, Poland, Turkey, Israel, Portugal, Romania, Argentina, Bulgaria, Canada, Croatia, Czechia, Lithuania, Mexico, Philippines, United... and more
Hoffmann-La Roche

Recruiting

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy (Astefania)

Breast Cancer

Korea, Republic of, United States, Australia, China, Ukraine, Spain, United Kingdom, Turkey, Mexico, Brazil, Austria, Belgium, Denmark, Germany, Greece, Russian Federation, Taiwan, France, Kenya, New Zealand, Portugal, Thailand, Rom... and more
Novartis Pharmaceuticals

Active, not recruiting

A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive

United States, China, Hungary, Japan, Belgium, Germany, Canada, Singapore, Australia, Israel, Netherlands, Spain, Italy, Korea, Republic of, Bulgaria, France, United Kingdom, Czechia, Sweden, India, Malaysia, Denmark, Taiwan, Norway, Fi... and more
Novartis Pharmaceuticals

Recruiting

CINC424A2X01B Rollover Protocol

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Thalassemia | Graft Versus Host Disease

Korea, Republic of, Italy, Belgium, Japan, Germany, Australia, Bulgaria, Chile, China, Denmark, Greece, Hungary, Israel, Lebanon, Poland, Portugal, Russian Federation, Slovakia, South Africa, Spain, Sweden, Thailand, India, Mexico, Turkey, Fran...
Hoffmann-La Roche
Chugai Pharmaceutical

Active, not recruiting

A Phase III Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated With Complement Inhibitors. (COMMODORE 2)

Paroxysmal Nocturnal Hemoglobinuria

Spain, Korea, Republic of, France, Sweden, Thailand, Malaysia, China, Turkey, Netherlands, Japan, Australia, United Kingdom, Germany, South Africa, Brazil, Romania, Argentina, Poland, Greece, Hong Kong, Lithuania, Mexico, Philippines, Portuga... and more
Novartis Pharmaceuticals

Completed

A Randomized Phase III Study to Assess the Effect of a Longer Duration of Consolidation Treatment With Nilotinib on TFR in CP CML. (ENESTPath)

Philadelphia Chromosome Positive (PH+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)

Germany, Belgium, France, Italy, Spain, Hungary, Austria, Sweden, Bulgaria, Denmark, Greece, Slovenia, United Kingdom, Czechia, Romania, Serbia, Slovakia, Portugal, Finland, Norway, Poland
Hoffmann-La Roche
Chugai Pharmaceutical

Recruiting

A Study Evaluating The Safety, Pharmacokinetics, and Efficacy Of Crovalimab Versus Eculizumab In Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors (COMMODORE 1)

Paroxysmal Nocturnal Hemoglobinuria

United States, Korea, Republic of, Spain, Germany, Estonia, Japan, Colombia, Saudi Arabia, Turkey, Brazil, France, Greece, Poland, Taiwan, Netherlands, Italy, Australia, Sweden, Singapore, Portugal, Hungary, Belgium, Canada, Czechia, Hong... and more
Nektar Therapeutics
Bristol-Myers Squibb

Terminated

Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence (PIVOT-12)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, France, Australia, Italy, Greece, Israel, Russian Federation, New Zealand, Austria, United Kingdom, Netherlands, Portugal, Poland, Czechia, Romania
Celgene

Completed

Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) (tnAcity)

Breast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...

United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
Amgen

Completed

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Leukemia, Acute Lymphoblastic

Italy, United Kingdom, Belgium, Mexico, Germany, Russian Federation, Turkey, Spain, Australia, Poland, Austria, Czechia, France, Portugal, Israel, Denmark, Brazil, Romania, Sweden, Switzerland, Norway, Netherlands, Argentina, Greece

Clinical Trials on Recurrent Myelodysplastic/Myeloproliferative Neoplasm in Portugal

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mongolia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations